-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Advances in GvHD: Expert Guidance on the Current Treatment Landscape, Optimizing Prophylaxis, and Integrating Novel Therapies

Sponsor: an educational grant from Incyte Corporation. Provided by Clinical Care Options, LLC.
Program: Satellite Symposia
Hematology Disease Topics & Pathways:
autoimmune disorders, Biological, HSCs, Adult, Diseases, GVHD, Therapies, cell regulation, Elderly, Biological Processes, Immune Disorders, Cell Lineage, Study Population, transplantation, immune mechanism
Friday, December 4, 2020: 11:00 AM-2:00 PM
Chair:
Corey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute
Disclosures:
Cutler: Elsalys, Fresenius Kabi, Genentech, Generon, Incyte, Jazz, Kadmon, Medsenic, Omeros, and Pharmacyclics: Consultancy.
Speakers:
Nelson J. Chao, MD, MBA, Duke University and David B. Miklos, MD, PhD, Stanford University Medical Center
Disclosures:
Miklos: Kite-Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Research Funding; Janssen: Consultancy, Other: Travel support; Miltenyi Biotec: Research Funding; Allogene Therapeutics Inc.: Research Funding; Juno-Celgene-Bristol-Myers Squibb: Consultancy, Other: Travel support, Research Funding; Pharmacyclics: Consultancy, Other: Travel support, Patents & Royalties, Research Funding; Novartis: Consultancy, Other: Travel support, Research Funding; Adaptive Biotech: Consultancy, Other: Travel support, Research Funding.
During this webinar, learners can expect to receive review and panel discussion on advances/latest practice-changing data surrounding the most recent developments and emerging novel therapies for GvHD (including, but not limited to, the current treatment landscape, strategies in GvHD prophylaxis, and emerging therapies for patients with aGvHD and cGvHD). The selected format for this program features peer-to-peer discussion and direct expert faculty interaction with the audience. In addition, expert faculty will provide webinar attendees with a comprehensive understanding of practical approaches to patient management that will enhance their ability to integrate insights upon their return to the clinic. Each portion of the program will include a case review and didactic presentation by an expert faculty member followed by a moderated panel discussion and audience Q&A session. Faculty will discuss key clinical questions, available evidence, and challenges that affect clinical decisions as well as their individual management recommendations for each case. Throughout the program, learners will be able to vote on case scenarios and directly submit questions to the panel for their consideration. Discussion topics will include:

  • Updates in Diagnostic and Prognostic Biomarkers in GvHD
  • Optimizing Prophylaxis Strategies for GvHD
  • Recent Advances in aGvHD and cGvHD Therapy
See more of: Satellite Symposia